Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 12, 2008, Pages 4664-4671

  Wilkens, Julia ^a   Chwalisz, Kristof ^c,i   Han, Cong ^c,j   Walker, Jane ^d   Cameron, Iain T ^e   Ingamells, Susan ^e   Lawrence, Alexandra C ^e   Lumsden, Mary Ann ^f   Hapangama, Dharani ^g   Williams, Alistair R W ^b   Critchley, Hilary O D ^a,h  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ ABBOTT LABORATORIES   (United States)

^j TAKEDA PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASOPRISNIL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROGESTERONE RECEPTOR MODULATOR; TRANEXAMIC ACID;

ABDOMINAL PAIN; ARTERY BLOOD FLOW; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DYSMENORRHEA; ECHOGRAPHY; FEMALE; HEADACHE; HUMAN; HYSTERECTOMY; MENSTRUATION; NAUSEA; OVARY FUNCTION; PERIOPERATIVE COMPLICATION; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT; UTERINE ARTERY; UTERUS MYOMA;

EID: 57349169309     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1104     Document Type: Article

References (33)

1. Stewart EA 2001 Uterine fibroids. Lancet 357:293-298
2. Flake GP, Andersen J, Dixon D 2003 Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111:1037-1054
3. Edozien LC 2005 Hysterectomy for benign conditions. BMJ 330:1457-1458
4. Edwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, Murray GD 2007 Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 356:360-370
5. Lepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B, Kieke BA, Wilcox LS 1997 Hysterectomy surveillance: United States, 1980-1993. MMWR CDC Surveill Summ 46:1-15
6. Rein MS 2000 Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108(Suppl 5):791-793
7. Maruo T, Matsuo H, Samoto T, Shimomura Y, Kurachi O, Gao Z, Wang Y, Spitz IM, Johansson E 2000 Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 65:585-592
8. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R, Leboff M 1993 A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 76:1439-1445
9. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS 2003 Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 101:243-250
10. Reinsch RC, Murphy AA, Morales AJ, Yen SS 1994 The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol 170:1623-1627; discussion 1627-1628
11. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W 2005 Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 26:423-438
12. Schubert G, Elger W, Kaufmann G, Schneider B, Reddersen G, Chwalisz K 2005 Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11β-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 23:58-73
13. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K 2000 Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 65:713-723
14. Chwalisz K, DeManno D, Garg R, Larsen L, Mattia-Goldberg C, Stickler T 2004 Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 22:113-119
15. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA 2007 A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 87:1399-1412
16. Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, Chwalisz K 2007 The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 22:1696-1704
17. Tekay A, Jouppila P 1996 Intraobserver reproducibility of transvaginal Doppler measurements in uterine and intraovarian arteries in regularly menstruating women. Ultrasound Obstet Gynecol 7:129-134
18. Valentin L, Sladkevicius P, Bland M 2001 Intraobserver reproducibility of Doppler measurements of uterine artery blood flow velocity in premenopausal women. Ultrasound Obstet Gynecol 17:431-433
19. Sulaiman S, Khaund A, McMillan N, Moss J, Lumsden MA 2004 Uterine fibroids: do size and location determine menstrual blood loss? Eur J Obstet Gynecol Reprod Biol 115:85-89
20. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM 2001 Determination of total menstrual blood loss. Fertil Steril 76:125-131
21. Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM 2002 The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99:290-300
22. Yong EL, Glasier A, Hillier H, Ledger W, Caird L, Beattie G, Sweeting V, Thong J, Baird DT 1992 Effect of cyclofenil on hormonal dynamics, follicular development and cervical mucus in normal and oligomenorrhoeic women. Hum Reprod 7:39-43
23. Santoro N, Crawford SL, Allsworth JE, Gold EB, Greendale GA, Korenman S, Lasley BL, McConnell D, McGaffigan P, Midgely R, Schocken M, Sowers M, Weiss G 2003 Assessing menstrual cycles with urinary hormone assays. Am J Physiol Endocrinol Metab 284:E521-E530
24. Brown A, Cheng L, Lin S, Baird DT 2002 Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 87:63-70
25. Farmakides G, Stefanidis K, Paschopoulos M, Mamopoulos M, Lolis D 1998 Uterine artery Doppler velocimetry with leiomyomas. Arch Gynecol Obstet 262:53-57
26. Kanelopoulos N, Dendrinos S, Oikonomou A, Panagopoulos P, Markussis V 2003 Doppler-ultrasound as a predictor of uterine fibroid response to GnRH therapy. Int J Gynaecol Obstet 82:41-47
27. Pepper J, Dewart PJ, Oyesanya OA 1999 Altered uterine artery blood flow impedance after danazol therapy: possible mode of action in dysfunctional uterine bleeding. Fertil Steril 72:66-70
28. Chen W, Ohara N, Wang J, Xu Q, Liu J, Morikawa A, Sasaki H, Yoshida S, Demanno DA, Chwalisz K, Maruo T 2006 A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 91:1296-1304
29. Ohara N, Morikawa A, Chen W, Wang J, DeManno DA, Chwalisz K, Maruo T 2007 Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 14:20-27
30. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, Roark M, Steinkampf MP 1993 An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 76:1217-1223
31. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L 2005 The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 20:1090-1099
32. Friedman AJ, Lobel SM, Rein MS, Barbieri RL 1990 Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 163:1114-1119
33. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD 2004 Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224-1229